Efficacy and safety of novel immune checkpoint inhibitor ‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis

ConclusionPD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-na ïve ES-SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent.

Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li Tags: ORIGINAL ARTICLE Source Type: research